Xenetic Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on May 15, 2020. The report discloses the entry into a Material Definitive Agreement with Scripps Research regarding the advancement of the Company's personalized Chimeric Antigen Receptor T-Cell technology, XCART.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data point disclosed is the commitment to provide up to $3.0 million in research funding to Scripps Research.
Material Changes and Agreement Details
- Agreement Type: Research Funding and Option Agreement with Scripps Research.
- Total Funding Commitment: Up to $3.0 million.
- Payment Schedule: Quarterly payments of approximately $300,000 over a 27-month period, with an initial payment of approximately $300,000 due on the agreement date.
- Term: Three years from the date of the agreement, unless earlier terminated.
- Licensing Rights: The Company received a license to existing Patent Rights or Technology within the defined Field. Additionally, the Company secured an option to acquire a worldwide exclusive license to other Scripps Research rights and a non-exclusive, royalty-free license for internal research purposes.
- Termination: The Company may terminate with 30 days' written notice. Scripps Research may terminate for nonpayment (subject to a 30-day cure period) or uncured failure to perform obligations.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance or management commentary on future earnings. The primary risk disclosed relates to the Company's obligation to make timely payments to maintain the agreement; failure to do so could result in termination by Scripps Research. The agreement is also subject to termination in the event of either party's bankruptcy.
Key Facts for Investor Verification
- Verify the impact of the $3.0 million funding commitment on the Company's current cash position and liquidity.
- Confirm the specific scope of the "Field" and the Technology covered under the new license and option rights.
- Monitor the Company's ability to meet the quarterly payment schedule of approximately $300,000.
- Review the full text of the Agreement when filed as an exhibit to the next Form 10-Q for detailed terms not summarized here.